Interview with Jacek Barlinski, Country Manager, Nycomed Poland
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Address: SymPhar Sp. z.o.o.
ul. Włoska 1
Warsaw 00-777
Poland ,Poland
Tel: (022) 822 93 06
We are a young Polish pharmaceutical company with Australian roots. We integrate the timeless values of both cultures for the benefit of patients and customers.
The original inhabitants of Australia believed that the kangaroo was a symbol of physical and spiritual strength and a guide who protected them and showed them the right way. We have used this timeless icon as our logo to demonstrate our strength, speed and determination, but at the same time as a symbol of our commitment to the right way, both in a strategic and ethical context.
SymPhar shows the way.
SymPhar is a multidimensional company:
We cooperate with Polish and international companies in bringing the benefits of their products to Polish health care professionals, patients and consumers.
We assist smaller European companies with products filling valuable therapeutic niches in making their products available in Poland.
We supply our own products to the Polish market. These are products identical in composition, efficacy and safety to well-known “Big Pharma” products but at a much reduced cost. We don’t invest huge amounts in promotion, therefore we can provide these essential medical products at a price which suits the Polish pocket.
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your…
Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in…
With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market,…
Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and…
The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in…
Stretching across the heart of continental Europe, Poland is a massive bridge that links east and west, old and new, and which epitomizes a changing continent. At one time…
See our Cookie Privacy Policy Here